Ibrutinib is a generic form of brand name of Imbruvica. Imbruvica 70mg is a small molecule which work as an irreversible potent inhibitor of Burton's tyrosine kinase.
Imbruvica 70mg designated as a targeted covalent drug and it show a very promising activity in B cell malignancies.
Imbruvica 70mg is a prescription drug which is used under the guidance by medical practioners


The drug Imbruvica 70mg is indicated for adults for the condition as follows :
Chronic graft versus host disease (cGVHD) after failure of ≥1 lines of systemic treatment.
Marginal zone lymphoma (MZL) in patients who require systemic therapy and have administer at least 1 prior anti-CD20-based therapy. All lines of therapy for Waldenström macroglobulinemia (WM), a rare, indolent type of non-Hodgkin lymphoma (B-cell lymphoma); may be needed as a single agent or in combination with rituximab
Mantle cell lymphoma (MCL) in patients who have administer at least 1 previous therapy
Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL); also indicated for CLL/SLL with 17p deletion; may be needed as a single agent, or in combination with rituximab and bendamustine

Dosage and administration

Dosage for patients with Mantle Cell Lymphoma :
The recommendeddose is 560mg (four 140mg-mg capsules) PO qDay.
Follow until disease progression or undesirable toxicity
Dosage for patients with Waldenström Macroglobulinemia
The recommended dose is 420mg (three 140mg capsules) per oral qDay
When combination with rituximab is 420 mg PO qDay plus rituximab administered weekly for 4 consecutive weeks (weeks 1-4) continued by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20)
Dosage for patients withChronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
The recommended dose is 420mg (three 140mg capsules) per oral qDay
While in combination with bendamustine and rituximab the usual dose is 420mg PO qDay administrated q28d for up to 6 cycles until progression or undesirable toxicity
Dosage for patients with Marginal Zone Lymphoma
The recommendeddose is 560mg (four 140mg-mg capsules) PO qDay.
Follow until disease progression or undesirable toxicity
Dosage for patients with Graft vs Host Disease
The recommended dose is 420mg (three 140mg capsules) per oral qDay
Follow until cGVHD progression, recurrence of an underlying malignancy, or undesirable toxicity occurs.

Mechanism Of Action

Burton’s tyrosine kinase (BTK) inhibitor involved in Ibrutinib which forms a covalent bond with a cysteine residue in the BTK active site, leading to prevention of BTK enzymatic activity. Thereby BTK is a signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways
BTK’s role in signalling via the B-cell surface receptors reports in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion


Peak plasma concentration of Imbruvica is 1-2 hours and drug taking with food will increases ibrutinib exposure.
Imbruvica has plasma protein level is 97.3% and volume of distribution is 10,000L
Ibrutinib is Metabolized to various metabolites primarily by cytochrome P450 CYP3A, and to a minor extent by CYP2D6
Ibrutinib was excretion through feces 80% and urine 10 %
Half-life of ibrutinib is 4-6 hours


Some other malignancies (5-14%) reported involving carcinomas (1-3%); the most frequent second primary malignancy was nonmelanoma skin cancer (4-11%)
Hypertension reported with a median time to onset of 4.6 months; regulate for new onset hypertension or hypertension which is not adequate controlled after starting ibrutinib
Tumor lysis syndrome at times resulted; assess the baseline risk (eg, high tumor burden) and take applicable precautions
Imbruvica 40mg will cause fetal risk when administered to a pregnant woman
lethal and serious cases of kidney failure occur; treatment-emergent have high in creatinine levels up to 1.5 x ULN occurred in 67% (MCL) and 23% (CLL) and from 1.5-3x ULN in 9% (MCL) and 4% (CLL); regularly monitor creatinine and maintain hydration

Drug Interaction

Interaction of Imbruvica 70mg with strong or moderate CYP3A inhibitor will increase ibrutinib plasma concentrations along with have high risk of drug related toxicity
Interaction of Imbruvica 70mg with strong or moderate CYP3A inducers will decrease ibrutinib plasma concentrations.

Side Effects

More common side effects of Imbruvica 70mg :
• Nausea
• Diarrhea
• Reduced neutrophils
• Decreased haemoglobin
• Fatigue
• Bruising
• Low platelets
• Musculoskeletal pain
• Swelling
• Upper respiratory tract infection.
Less common side effects of Imbruvica 70mg :
• Constipation
• Rash
• Sinusitis
• Headache
• Dehydration
• Dyspepsia
• Petechiae
• Arthralgia
• Nosebleeds
• Abdominal pain
• Vomiting
• Decreased appetite
• Cough
• Fever
• Stomatitis
• Dizziness
• Urinary Tract Infection
• Pneumonia
• Skin infections
• Asthenia
• Muscle spasms
• Shortness of breath.

Missed Dose

if dose missed, patients should consult with medical practitioner and follow the instructions given by them.
thereby missed dose should be avoid and follow the regular dosing schedule


Store the drug at 200C- 250C


Pregnancy category is D; while taking Imbruvica 70mg avoid becoming pregnancy and for up to 1 month after ending treatment.


Avoid breast feeding during treatment with Imbruvica 70mg


Hypersentivity reaction

Connect With Us

Prescription Medication Policy

1. Anti-Cancer-Drugs.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. Anti-Cancer-Drugs.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the Anti-Cancer-Drugs.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. Anti-Cancer-Drugs.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Anti-Cancer-Drugs.com
6. At Anti-Cancer-Drugs.com, a Caregiver can order prescription medicines on your behalf.